Press Releases

73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour typesContinued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation,...

Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients. Late-breaking Phase 2 data evaluates risankizumab, an anti-IL-23 monoclonal biologic antibody for...

Bayer announced that data from several studies across its oncology portfolio will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 3-7 in Chicago, Illinois (USA). The...

Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression Therapeutic Factor IX activity sustained at levels exceeding those considered sufficient to reduce the risk of joint bleeds and...

Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program will generate additional data on symptom reduction, efficacy, safety, quality of...

New Analysis From Phase 3 Trial of Kyprolis® (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma Patients With Early Disease ProgressionPhase 1/3 MASTERKEY-265 Study Abstracts Present Data on IMLYGIC® (Talimogene Laherparepvec) in Combination With Pembrolizumab in Patients With Unresected Stage...

14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced...